Summary
The European pharmaceutical industry faces significant uncertainty amid potential U.S. tariffs on medical and pharmaceutical products, a development that threatens to disrupt one of the most integrated transatlantic trade relationships. In 2023, the European Union exported approximately €90 billion ($97 billion) worth of pharmaceutical goods to the United States, underscoring the economic interdependence of the two regions in this vital sector. European countries such as Ireland, Belgium, Denmark, and Germany serve as key hubs for pharmaceutical manufacturing, hosting production facilities of major U.S.-based companies like Pfizer, Johnson & Johnson, and Eli Lilly.
The tariff threat emerged from the trade policies of the Trump administration, which sought to bolster U.S. domestic manufacturing through protectionist measures. Although pharmaceuticals were initially exempt from broad tariffs on imports like steel and aluminum, the sector later became a target under national security justifications, with proposed tariffs reportedly reaching up to 25%. These moves have raised concerns across Europe about potential economic fallout, including higher production costs, disruption of complex supply chains, and diminished funding for research and development. European policymakers have emphasized the need to strengthen domestic pharmaceutical production and supply chain resilience, particularly in light of vulnerabilities exposed by the COVID-19 pandemic.
The prospect of tariffs has intensified tensions between the U.S. and the EU, with risks of retaliatory measures that could further destabilize pharmaceutical trade and increase healthcare costs for patients on both continents. Industry leaders warn that relocating manufacturing to the U.S. to avoid tariffs would be costly and time-consuming, potentially diverting resources away from innovation and future medicine development. The European Commission’s Pharmaceutical Strategy for Europe aims to enhance the sector’s competitiveness and crisis preparedness, but the tariff menace adds complexity to these efforts.
As the situation evolves amid ongoing political and economic uncertainty, stakeholders from industry and government continue to debate the best path forward. The outcome of U.S. trade policy and the 2024 presidential election will likely shape the future of EU-U.S. pharmaceutical relations, highlighting the delicate balance between protectionism and global cooperation in a sector critical to public health.
Background
The pharmaceutical industry in Europe has long been intertwined with global trade dynamics, particularly with the United States, which remains one of its largest export markets. In 2023, EU medical and pharmaceutical product exports to the United States totaled approximately €90 billion ($97.05 billion), reflecting the deep economic integration between the two regions in this sector. European countries such as Ireland, Belgium, Denmark, and Germany serve as major pharmaceutical hubs, hosting production facilities of leading US companies like Pfizer, Johnson & Johnson, and Eli Lilly, and collectively accounting for a significant portion of EU pharmaceutical exports.
Historically, the trade relationship between Europe and the US has been shaped by shifting policies and economic strategies. Until the 1940s, the United States adopted a protectionist stance, imposing tariffs to shield its domestic industries, including pharmaceutical manufacturing, from foreign competition. Following World War II, the US shifted towards more cooperative trade relations with Europe, recognizing the continent as a vital partner for both economic recovery and security. Despite this evolution, tensions over trade policies have periodically resurfaced, with tariff threats emerging as a contentious issue.
Under the administration of President Donald Trump, tariffs became a prominent tool in US trade policy aimed at bolstering domestic industries and addressing perceived trade imbalances. While pharmaceuticals were initially exempt from sweeping tariffs on US imports, Trump later indicated plans to impose separate tariffs on the sector as part of his broader agenda to reshore manufacturing and strengthen the US economy. This approach was justified by the administration as a means to restore national and economic security, with tariffs seen as responsive measures to unfair foreign trade practices.
In response, European pharmaceutical companies and industry groups voiced concerns about the potential consequences of such tariffs. They warned of the risk of an exodus of pharmaceutical production to the US, the negative impact on innovation due to reduced research and development funding, and disruptions to highly interconnected supply chains that span both sides of the Atlantic. The European Commission and its health and food safety commissioner, Stella Kyriakides, highlighted vulnerabilities exposed by the COVID-19 pandemic and emphasized the need for a robust and resilient pharmaceutical manufacturing base within Europe.
The European Commission’s Pharmaceutical Strategy for Europe, adopted in November 2020, reflects these priorities by aiming to create a future-proof regulatory framework that supports innovation, sustainability, and crisis preparedness, while addressing market failures and ensuring diversified and secure supply chains. However, the looming threat of US tariffs introduces uncertainty for the sector, potentially undermining these efforts and triggering retaliatory measures that could disrupt transatlantic pharmaceutical trade and raise healthcare costs for patients on both continents.
Tariff Threats and Trade Tensions
Since the Trump administration initiated tariffs targeting various sectors, the European pharmaceutical industry has faced increasing uncertainty and trade tensions with the United States. While pharmaceuticals were initially exempted from the broad tariffs imposed on other imports such as steel and aluminum, they have become a focal point for potential tariff deployment due to national security concerns related to foreign dependence on drug production.
The U.S. relies heavily on pharmaceutical imports from Europe, with 2023 Eurostat data showing EU medical and pharmaceutical exports to the U.S. totaled approximately €90 billion ($97.05 billion). The U.S. market remains the largest globally for pharmaceutical sales, accounting for nearly 50% of worldwide sales, making it a critical market for European pharma companies. Despite this mutual economic reliance, the U.S. government’s probe into pharmaceutical imports and the proposal of tariffs—reportedly up to 25%—pose significant risks to the transatlantic trade relationship.
The imposition of tariffs on European pharmaceuticals could lead to higher drug prices in the U.S., disrupt complex supply chains, and place financial strain on healthcare providers and patients. Moreover, such measures risk provoking retaliatory tariffs from the European Commission targeting major U.S. pharmaceutical firms operating in Europe, including companies like Pfizer, Merck, and Johnson & Johnson. This tit-for-tat dynamic threatens to exacerbate supply issues on both sides of the Atlantic and could have broad implications for access to critical medications such as cancer treatments and diabetes medicines.
In response to the looming tariffs, European pharmaceutical companies have been expanding production facilities within the United States, aiming to mitigate tariff impacts and strengthen local supply chains. However, the full industry response remains uncertain, with potential shifts in drug manufacturing and clinical trial locations yet to be seen. The European Commission has also expressed readiness to implement countermeasures in a “well calibrated and timely response” to any U.S. tariff impositions.
This escalating tariff threat comes amidst ongoing debates about trade policies and protectionism in the U.S., where past administrations have balanced open trade with national economic interests. A 2024 study suggested that some tariffs introduced under Trump strengthened the U.S. economy and encouraged reshoring in industries like manufacturing and steel, but the pharmaceutical sector presents unique challenges due to its globalized and specialized supply chains.
Looking ahead, the 2024 U.S. presidential election outcome could significantly influence the trajectory of U.S.-EU pharmaceutical trade relations. Proposed tariffs ranging from 10% to as high as 60% on imports, especially those sourced from China, could further disrupt established supply chains and increase costs for American consumers, while deepening tensions with European trade partners. As the situation develops, both sides remain cautious, aware that a protracted trade war in pharmaceuticals would be costly and damaging for industry stakeholders and patients alike.
Effects on the European Pharmaceutical Sector
The prospect of U.S. tariffs on European pharmaceutical imports poses significant risks to the European pharmaceutical sector, potentially triggering widespread economic and operational disruptions. Ireland and Denmark, two countries heavily reliant on pharmaceutical manufacturing and exports, are expected to be the most affected. In Ireland, the industry employs approximately 45,000 people and exports to the U.S. exceed €72 billion, making tariffs a serious economic threat. Similarly, Denmark’s economic growth has been closely tied to expansions in pharmaceutical companies like Novo Nordisk, which contributed nearly half of the country’s GDP growth in 2023.
Beyond these countries, other European pharmaceutical hubs such as Belgium—which accounts for 15% of its total exports in pharmaceuticals and sent 25% of those exports to the U.S. in the first 10 months of 2024—would also face economic fallout. Tariffs could disrupt these established supply chains, leading to increased production costs, supply instability, and higher drug prices both in Europe and the U.S.. The interconnected nature of the transatlantic supply chain means that such trade barriers risk worsening medicine availability and access to lifesaving drugs, harming patients on both continents.
The imposition of tariffs might also encourage pharmaceutical companies to reconsider their investment and production strategies. Some firms may explore relocating production to the U.S. to avoid tariffs, although such moves would be costly and time-consuming—building a new facility can require up to $2 billion and take 5 to 10 years to become operational. Industry leaders warn that diverting resources to establish new manufacturing bases could come at the expense of pharmaceutical research and development, ultimately hindering innovation and future medicine discovery.
At a broader level, U.S. tariffs threaten to destabilize global pharmaceutical supply chains that rely heavily on key regions like China and India for active pharmaceutical ingredients (APIs) and intermediates. Over the past two decades, Europe has become increasingly dependent on these non-EU sources, with approximately one in six APIs needed in Europe exclusively produced in China. This geographic concentration has exposed Europe to vulnerabilities from geopolitical and environmental risks, which tariffs could exacerbate by incentivizing reshoring efforts and supply chain reconfigurations.
In response to these challenges, the European Commission has advanced regulatory strategies such as the Pharmaceutical Strategy for Europe, which aims to enhance the industry’s competitiveness, sustainability, and crisis preparedness, including diversifying supply chains and addressing medicine shortages. Moreover, policies like the proposed Critical Medicines Act suggest a “Buy European” principle to prioritize domestic pharmaceutical companies for government contracts, potentially sidelining American firms and complicating transatlantic trade dynamics.
Pharmaceutical industry stakeholders have expressed strong concerns about the wider consequences of tariffs on global supply chains, medicine availability in Europe, and regulatory barriers within the EU. There is also apprehension that increased protectionism could hinder transatlantic research partnerships, affecting collaborative clinical trials, data sharing, and overall innovation. Despite these risks, some large European pharmaceutical companies with substantial market presence believe they could absorb the additional costs imposed by tariffs, although this may not hold for smaller firms or the broader sector.
Responses from the European Pharmaceutical Industry
The European pharmaceutical industry has expressed significant concern over the prospect of U.S. tariffs on pharmaceutical products, warning that such measures could trigger a disruptive shift in investment and manufacturing away from Europe toward the United States. Industry leaders, including members of the European Federation of Pharmaceutical Industries and Associations (EFPIA), have urged the European Commission for “rapid and radical action” to mitigate the risk of an industry exodus, highlighting that approximately €16.5 billion ($18 billion) in biopharma investment within the EU could be jeopardized in the near term.
Pharmaceutical companies have emphasized the complex, interconnected nature of supply chains that span Europe, China, and India, cautioning that any interruption caused by trade barriers or tariffs would not only affect manufacturing but also patient access to critical medicines. They have called for a comprehensive approach addressing the entire supply chain, including active pharmaceutical ingredients (APIs), intermediates, and chemical building blocks, noting that many specialized pharmaceutical chemistries have already diminished in Europe due to stringent environmental regulations such as REACH.
European pharma executives have highlighted the potential consequences of U.S. tariffs on both sides of the Atlantic. They argue that tariffs could increase drug costs, create barriers to patient access, and ultimately undermine public health objectives that both the EU and U.S. governments prioritize. Furthermore, they caution that retaliatory tariffs from the EU might exacerbate supply problems and do not offer a constructive solution to the challenges faced by the industry.
In response to these challenges, the industry has called for policy reforms within the EU to enhance competitiveness and innovation. Proposals include simplifying clinical trial procedures, digitalizing the European health system, and strengthening intellectual property protections to make the region more attractive for pharmaceutical R&D and manufacturing. The industry also advocates for increased domestic production capacity to reduce reliance on imports, thereby enhancing crisis preparedness and supply chain resilience.
Despite the threat posed by tariffs, the industry stresses the high costs and lengthy timelines associated with relocating manufacturing facilities to the United States, which can take up to a decade and require investments of approximately $2 billion. Such shifts would divert funds from research and innovation, ultimately hampering the development of future medicines. Therefore, many in the sector view the current supply arrangements as fundamentally sound and caution against “fixing something that is not broken”.
Government and Regulatory Reactions
The proposed U.S. tariffs on European pharmaceutical products have elicited a range of responses from European governments and regulatory bodies, reflecting concerns over potential disruptions to trade and supply chains. Ireland’s Department of Foreign Affairs emphasized the importance of a coordinated EU response, stating it “will work with EU partners to measure the impact of tariffs across all sectors, and calibrate our response on that basis.” The department further highlighted that increased protectionism would be detrimental not only to the EU and Ireland but also to the global economic environment.
At the European Union level, regulatory and policy discussions have intensified in light of the tariff threat. The European Commission has considered measures such as the Critical Medicines Act, which proposes a “Buy European” principle for essential medicines. This initiative could prioritize European pharmaceutical companies in large-scale government contracts, potentially sidelining U.S. firms. Additionally, the tariff threat has rekindled debates surrounding the EU’s stalled General Pharmaceutical Legislation (GPL) reform, which has been under negotiation since 2023.
The European Commission’s Pharmaceutical Strategy for Europe, adopted in 2020, also serves as a strategic framework aimed at enhancing the EU pharmaceutical sector’s resilience. It focuses on fostering innovation, ensuring supply chain security, and addressing market failures to better prepare for crises and potential trade disruptions. This strategy underpins efforts to strengthen the domestic manufacturing base, including APIs, intermediates, and building blocks, which have historically declined in Europe due to stringent environmental regulations such as REACH.
European industry stakeholders and lobby groups, including Europabio and Medicines for Europe, have urged the EU to accelerate initiatives like the EU Biotech Act to enhance competitiveness and secure supply chains. However, some European pharmaceutical companies with substantial operations in the region have downplayed concerns over tariffs, expressing confidence in their ability to absorb potential costs.
On the U.S. side, government signals have been mixed. While the Trump administration has announced tariffs on various trade partners, some measures have been suspended, delayed, or allowed exceptions, contributing to uncertainty about the final scope and enforcement of tariffs on European pharmaceuticals. This ambiguity complicates regulatory planning and international cooperation, especially in areas such as joint research, data sharing, and clinical trials.
Future Outlook
The future of the European pharmaceutical industry faces significant uncertainty due to the threat of U.S. tariffs and broader geopolitical tensions. Industry leaders have warned that without swift and radical policy reforms in Europe, pharmaceutical research and development (R&D) and manufacturing investments may increasingly shift toward the United States. A recent survey by the European Federation of Pharmaceutical Industries and Associations (EFPIA) indicated that approximately €16.5 billion in biopharma investment within the EU-27 could be at risk within just a few months, highlighting the urgency for regulatory and strategic responses.
Europe’s heavy reliance on global supply chains, particularly for active pharmaceutical ingredients (APIs) and other key components, poses vulnerabilities that have been starkly exposed by recent crises such as the COVID-19 pandemic. Calls for enhancing the domestic manufacturing base have gained traction, emphasizing the need to reintroduce pharmaceutical production within Europe to ensure greater self-sufficiency and supply chain resilience. However, the complexity of pharmaceutical chemistry and stringent environmental regulations, such as the EU’s Registration, Evaluation, Authorisation
The content is provided by Harper Eastwood, Lifelong Health Tips
